©
2004 - 2008 |
||||||||||||||
|
|
January 2008
Northern California Melanoma Center
St. Mary's Medical Center, 6th Floor
450 Stanyan Street
San Francisco, CA 94117-1079
tel: 415.750.5660
fax: 415.750.4860
email: ncmc@chw.edu
web: http://www.melanomacenter.com
Adjuvant
Studies for patients who are clinically free of disease but at high risk for recurrence. These often involve agents aimed at boosting the immune responses.
- Analyses of Immunologic Responses in Patients Receiving Recombinant Human Granulocyte-Macrophage Stimulating Factor (GM-CSF, Sargramostim) As Adjuvant Therapy of Stage II (T4), III and IV Melanoma and its Association with Clinical Response, a Phase 2 Study. THIS PROTOCOL HAS COMPLETED ACCRUAL AND THERE ARE NO OPENINGS FOR ADDITIONAL PATIENTS.
Metastatic Disease
First-Line: Studies for patients with metastatic melanoma that cannot be surgically excised or treated by other means, such as radiation therapy. These studies are limited to patients who have not had prior chemotherapy.
- Temodar
(Temozolomide) and Sutent (SU11248) as Therapy for Patients with Malignant
Melanoma, A Phase I/II Study
- Abraxane® and Avastin as Therapy for Patients with Malignant Melanoma, a Phase II Study
- A Randomized, Open-Label Study of IMC-1121B with or without Dacarbazine in Patients with Metastatic Melanoma
- A
Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment
With 2 mg Intralesional Allovectin-7® Compared to Dacarbazine
(DTIC) or Temozolomide (TMZ) in Subjects With Recurrent Metastatic Melanoma
Second-Line: Studies for patients with metastatic melanoma who have had prior chemotherapy and experienced disease progression.
Third Line: Studies for patients with metastatic melanoma who have had up to two prior chemotherapy regimens and experienced disease progression.
Other: Compassionate: Studies for patients with metastatic melanoma who have had disease progression on previous treatment or could not tolerate previous treatment, and for whom no alternative drug or therapy is available.
Follow-on: Study for patients whose melanoma has responded to systemic treatment. Treatment under this study is aimed at consolidating and maintaining the remission.
